Finch Therapeutics Group Inc (FNCH)
2.28
-0.02
(-0.87%)
USD |
NASDAQ |
May 06, 16:00
2.28
0.00 (0.00%)
After-Hours: 16:08
Finch Therapeutics Group Research and Development Expense (Quarterly): 0.00 for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.203M |
| March 31, 2023 | 8.588M |
| December 31, 2022 | 11.55M |
| September 30, 2022 | 11.86M |
| June 30, 2022 | 13.92M |
| March 31, 2022 | 15.53M |
| Date | Value |
|---|---|
| December 31, 2021 | 14.80M |
| September 30, 2021 | 15.54M |
| June 30, 2021 | 13.96M |
| March 31, 2021 | 12.98M |
| December 31, 2020 | 8.567M |
| September 30, 2020 | 9.045M |
| June 30, 2020 | 8.135M |
| March 31, 2020 | 7.397M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2023
15.54M
Maximum
Sep 2021
9.505M
Average
10.30M
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 66.74M |
| Vanda Pharmaceuticals Inc | 24.34M |
| Sage Therapeutics Inc | 71.73M |
| BioSig Technologies Inc | 1.176M |
| Palisade Bio Inc | 1.733M |